SK bioscience Co.,Ltd. (KRX:302440)
South Korea flag South Korea · Delayed Price · Currency is KRW
41,300
+1,000 (2.48%)
Last updated: Jun 2, 2026, 3:00 PM KST

SK bioscience Cash Flow Statement

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-83,286-57,424-53,88122,318122,452355,139
Depreciation & Amortization
95,27591,01649,22534,76527,23618,775
Loss (Gain) From Sale of Assets
-30,983-30,979-14,25968.06434.6-23.62
Asset Writedown & Restructuring Costs
--1.411,154--
Loss (Gain) From Sale of Investments
-4,010-10,444-24,162-13,777-36,875-892.14
Provision & Write-off of Bad Debts
-239.42-25.41-81.7-29.33-21.08-9.4
Other Operating Activities
1,851-14,385-124,9253,240-29,807119,603
Change in Accounts Receivable
-24,636-19,883-2,47226,674-4,770-7,595
Change in Inventory
22,81231,52379,41052,888-96,230-70,337
Change in Accounts Payable
1,80915,840-1,243-7,683-52,75946,536
Change in Other Net Operating Assets
18,50397,270-35,632-90,271-54,62075,397
Operating Cash Flow
-2,770102,507-128,02029,346-124,958536,594
Capital Expenditures
-177,077-183,091-164,413-43,461-72,993-42,907
Sale of Property, Plant & Equipment
51,42351,35516,5290.5434.5747.08
Cash Acquisitions
-3,615-3,615-216,758---
Sale (Purchase) of Intangibles
-101,065-77,257-7,811-6,834-3,497-1,562
Investment in Securities
-91,941-150,768423,3297,377352,052-1,384,617
Other Investing Activities
900.231,6162,688-2,361-2,951-235.56
Investing Cash Flow
-324,266-361,76053,564-45,279272,647-1,421,940
Short-Term Debt Issued
---1,00048,74211,324
Long-Term Debt Issued
-50,049192,057---
Total Debt Issued
110,04950,049192,0571,00048,74211,324
Short-Term Debt Repaid
----45,425-16,196-50
Long-Term Debt Repaid
--9,244-10,791-51,039-55,031-35,521
Total Debt Repaid
-9,545-9,244-10,791-96,464-71,227-35,571
Net Debt Issued (Repaid)
100,50440,806181,266-95,464-22,485-24,247
Issuance of Common Stock
993.73794.775,680397.62,618983,256
Other Financing Activities
-0-0-4,4675,484--628.09
Financing Cash Flow
101,49841,600252,479-89,583-19,867958,380
Foreign Exchange Rate Adjustments
6,51010,5047,6537,253-561.8722.25
Net Cash Flow
-219,027-207,149185,676-98,262127,25973,056
Free Cash Flow
-179,846-80,584-292,433-14,114-197,951493,686
Free Cash Flow Margin
-27.03%-12.37%-109.30%-3.82%-43.34%53.14%
Free Cash Flow Per Share
-2296.19-1028.30-3787.93-183.27-2570.086686.61
Cash Interest Paid
12,22710,6763,5671,3972,6813,407
Cash Income Tax Paid
-6,7764,65825,639104,2108,987
Levered Free Cash Flow
-314,999-154,803-345,40813,402-203,405-
Unlevered Free Cash Flow
-308,305-148,929-343,10514,276-201,867-
Change in Working Capital
18,488124,75140,063-18,392-208,37944,001